Themes: the IVth Conference on Human Retroviruses and Opportunistic Infections. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

PI Perspect. 1997 Mar;(No 21):1-4. Unique Identifier : AIDSLINE AIDS/97702493

Abstract: Presentations at the Fourth Conference on Human Retroviruses and Opportunistic Infections revealed a growing consensus on AIDS research and treatment. The most encouraging aspects of treatment included consistent reductions in viral load, viral load reductions resulting from first-line use of two or more highly active antivirals, and patients with advanced disease appearing to have a profound antiviral response to the newer therapies. Researchers fear that the benefits of these new therapies will diminish, as with previous drugs. Also, many difficult questions remain unanswered, such as the degree of immune restoration that people can expect, what forms of restoration therapy will have the greatest effect, the long-term benefits, and the cost in terms of the body and of the human spirit. Societal consequences of advances in HIV therapy also plagued the conference. Concerns included the questionable impact of new HIV advances on the epidemic worldwide and overcoming the skepticism of the AIDS community about the hope offered by the new treatments. One risk resulting from these new therapies is that the media will overstate their success, leaving the public and the Congress with the view that AIDS is no longer a problem.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY/ VIROLOGY Anti-HIV Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE CD4 Lymphocyte Count Drug Therapy, Combination HIV Infections/*DRUG THERAPY/IMMUNOLOGY/VIROLOGY HIV-1/ISOLATION & PURIF Human Viral Load NEWSLETTER ARTICLE MEETING REPORT
970830
M9781256

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .